Overall, the observed outcomes are consistent with the clinical guidelines from both the American Diabetes Association (ADA) and the European Society of Cardiology (ESC), which recommend the use of SGLT2 inhibitors in T2DM patients who either have established cardiovascular disease or are at elevated risk for heart failure [26]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.